Scribe Therapeutics (SCTX) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Scribe Therapeutics is the larger company by market cap ($332.6 million vs $278.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SCTX | XFOR |
|---|---|---|
| Share price | $17.57 | $2.81 |
| Market cap | $332.63M | $278.60M |
| 1-day change | +7.59% | +1.44% |
| YTD return | — | -29.75% |
| 1-year return | — | -18.31% |
| P/E ratio (TTM) | — | 140.50 |
| EPS (TTM) | $-4.15 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.60 | $4.83 |
| 52-week low | $13.50 | $2.70 |
| Distance from 52-week high | -55.63% | -41.82% |
| Average volume | 356.27K | 849.98K |
| Shares outstanding | 18.93M | 99.15M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
SCTX vs XFOR FAQ
Which is bigger, Scribe Therapeutics or X4 Pharmaceuticals?
Scribe Therapeutics (SCTX) is larger, with a market capitalization of $332.63M compared with $278.60M for X4 Pharmaceuticals (XFOR).
Are Scribe Therapeutics and X4 Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.